Navigation Links
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
Date:11/3/2010

RICHMOND, Va., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2010.

Total revenues for the third quarter ended September 30, 2010 were $1.8 million, as compared to $2.5 million for the corresponding period in 2009.  The $0.7 million decline in revenue was entirely due to lower cost recovery in the most recent quarter from our IPLEX™ Expanded Access Program ("EAP") in Italy for the treatment of Amyotrophic Lateral Sclerosis ("ALS").  In 2009, the Company ceased patient enrollment in the EAP in order to preserve inventory for existing patients.Net loss for the third quarter of 2010 was $0.3 million, break even on a per share basis, compared with a net loss of $0.1 million, also break even on a per share basis, reported in the third quarter of 2009.  The $0.2 million change in net loss was primarily due to the $0.7 million decrease in revenues, noted above, and a $0.3 million decrease in investment income, which were largely offset by an overall reduction of $0.8 million in operating expenses.

The $0.8 million decrease in total expenses resulted from a $0.3 million reduction in research and development expenses ("R&D expenses") and a $0.5 million decline in selling, general and administrative expenses ("SG&A expenses").  The lower R&D expenses resulted largely from the elimination of IPLEX™ fill-finish costs which we incurred in the third quarter of 2009, while the reduced SG&A expenses were principally due to lower external market research and consultancy fees associated with our ongoing strategic review process.

Investment income for the 2010 third quarter was $345,000, as compared to $682,000 for the same period in 2009; as overall market returns declined in the current quarter versus
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Insmed to Host Third Quarter 2010 Conference Call
2. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
3. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
7. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
8. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
9. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
10. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
11. Hanger Orthopedic Group, Inc. Announces Early Tender Results of Offer to Purchase Outstanding 10-1/4% Senior Notes Due 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today ... Officer, will present at two upcoming investor conferences in ... on November 16th at 10:30 am at The Pierre ... Conference on November 29 at 11:50 am at The ...
... 2011 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2011. (Logo:   http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ) ... were $6.0 million, 3% higher than sales of $5.8 ... to increases in sales of the Company,s medical device ...
Cached Medicine Technology:Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 2Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 2Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 4Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 5
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced ... introduced this summer at the treatment center in Puerto Vallarta, Mexico. , The ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... insufficient scrotal support and protection against dribbled urine and sweat. "In order to ... Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... that pelvic imaging using computed tomography (CT) examinations are ... and eliminating this exam can significantly reduce a patient,s ... the pelvis during CT pulmonary angiography does not improve ... author for this study. He asserts, "Using CT venography ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
... Inhaled Beta-agonists Increase Survival Over Anticholinergics ... agents are commonly prescribed to manage chronic obstructive ... to decrease exacerbations and hospitalizations and improve COPD ... mortality. However, it is not known which therapy ...
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) -- The ... than the brains of normally developing children, and the difference ... The finding is a follow-up to earlier research that found ... of similarly aged normally developing kids, researchers said. ...
... Reporter , MONDAY, May 2 (HealthDay News) -- Kids who ... up getting injured more often, new research suggests. ... pursuit were almost twice as likely to get hurt as ... Neeru Jayanthi, medical director of primary care sports medicine at ...
... May 2 (HealthDay News) -- American workers forced to travel ... study suggests. A team of U.S. researchers found that ... are at higher risk for cardiovascular disease than "light" travelers who ... The team at Columbia University,s Mailman School of Public Health analyzed ...
Cached Medicine News:Health News:Chest journal news briefs, May 2011 issue 2Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Brains of Autistic Kids Still Larger at Age 4, 5 2Health News:Brains of Autistic Kids Still Larger at Age 4, 5 3Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 2Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: